Drug Target Review
JUNE 15, 2023
Hasson’s interest in drug discovery began early in his training, where he was able to work on chemical biology and microplate-based high throughput assays as a graduate student. After completing his postdoc, Sam undertook an industrial career in drug discovery, with an emphasis on neurodegenerative diseases, at Pfizer and then Amgen.
Broad Institute
JUNE 30, 2023
Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei. “I
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sygnature Discovery
FEBRUARY 11, 2022
We’re thrilled to be working with cutting-edge new Dutch biotech company River BioMedics to identify new drugs that directly treat heart failure and cardiovascular disease – the number one cause of death in the world. River BioMedics is progressing its cardiovascular disease programmes following a €1.8m
The Pharma Data
SEPTEMBER 8, 2021
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.
Drug Target Review
OCTOBER 10, 2024
What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Diseased cells are likely to be more fragile or less abundant, making it difficult to obtain enough for therapy.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.
Elrig
APRIL 29, 2024
My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK.
Expert insights. Personalized for you.
96 
Let's personalize your content